| 1 | Forty Seven Inc. | Stanford University | ~Q1 2017 (renegotiated/cleaned IP) | ~180 days | Gilead begins diligence → Acquisition (March 2020) | $4.9B | SEC S-1 2018; FierceBiotech CEO interview |
|---|
| 2 | Denali Therapeutics | UCSF | ~Q1 2018 (selective carve-out) | ~90 days | Filed BBB + LRRK2 IP → Takeda collaboration | $1.05B upfront + milestones | Denali 10-K 2018; BioCentury Q3 2018 |
|---|
| 3 | Alnylam | University of Massachusetts | ~2017–2018 (deprioritized UMass IP) | ~60 days | GalNAc platform patents issued, standalone → Sanofi/Regeneron deals | $700M+ total | Alnylam 10-K 2018; USPTO records |
|---|
| 4 | Aveo Oncology | Kyowa Hakko Kirin | July 2018 | ~45 days | Re-licensed tivozanib in Europe → LG Chem merger discussions | $566M acquisition | Aveo 10-Q 2018; EvaluatePharma |
|---|
| 5 | ImmunoGen | Takeda/Millennium | June 2022 | 28 days | ADC license to Huadong Medicine | $85M upfront + $300M milestones | ImmunoGen press release June 2022 |
|---|
| 6 | Zymeworks | Daiichi Sankyo | March 2022 | ~60 days | Filed new HER2 ADC IP, enabled Jazz deal | $50M upfront (Jazz); $325M total | SEC 8-K 2022; BioWorld Daily |
|---|
| 7 | Blueprint Medicines | Wellcome Trust | April 2015 | ~30 days | Filed novel FGFR IP → Launched BLU-554 | $775M upfront (Roche later) | SEC S-1 2015; company IP filings |
|---|
| 8 | Arcus Biosciences | Taiho Pharma | June 2020 | ~90 days | Started TIGIT/A2aR combo → Gilead deal | $175M upfront + $2.8B potential | Arcus 10-Q 2020; JPM slides |
|---|
| 9 | Sutro Biopharma | Celgene | October 2019 | ~45 days | Filed CD74 ADC IP; positioned for new ADC deals | $90–125M per program(later deals) | Sutro 10-Q 2019; BioCentury |
|---|
| 10 | Iovance Biotherapeutics | NIH | March 2017 (partial termination) | ~90 days | Filed proprietary TIL manufacturing IP → supported BLA | >$1B market cap uplift | Iovance S-1; NIH tech office |
|---|
(20min delay)